Drug & Device Safety

Conferences & Courses
Formulation Strategies for Improved Delivery of Biologics Formulation Strategies for Improved Delivery of Biologics
May 5-6, 2014 | Boston, MA
CHI' s Formulation Strategies for Improved Delivery of Biologics conference, May 5-6, 2014, Boston, MA, will discuss new formulation approaches designed to overcome biologics delivery issues through as chemical modifications, new formulations and deliver

Biologics Formulation and Delivery Biologics Formulation and Delivery
May 5-7, 2014 | Boston, MA
CHI’s Biologics Formulation and Delivery Summit, May 5-7, 2014, Boston, MA, will provide a forum for focused discussions on current challenges and opportunities in delivery of biotherapeutics.

PK/PD of Multi-Domain Proteins PK/PD of Multi-Domain Proteins
May 5-6, 2014 | Boston, MA
Cambridge Healthtech Institute’s Second Annual PK/PD of Multi-Domain Proteins will address how PK/PD and ADME are driving molecular construct design, modeling for multiple targets, and unique characteristics of ADCs, bispecifics, and fragments.




Life Science Media Library
Characterization and Analysis of Visible &Sub-Visible Particulates Characterization and Analysis of Visible &Sub-Visible Particulates
January 8, 2012 |
Sub-visible particles present in these biopharmaceutical products are a product quality attribute and a potential patient safety concerns yet to be fully explored. Early and consistent particle detection, quantitation and control throughout the product life cycle of these drugs from development to commercial lot release is critical in mitigating any concerns. This requires appropriate analytical methods which can be applied to biopharmaceuticals across a large variety of protein concentrations and modes of administration. This DVD will cover strategies to utilize complementary methods and techniques at different phases of product development.
Immunogenicity Prediction and Mitigation Immunogenicity Prediction and Mitigation
November 18, 2011 |
Escherichia coli has proven its worth as a protein expression platform. Currently, E.coli is not viewed so much as an ‘alternative’ platform, but as a viable choice for achieving high-level expression of human genes and proteins at a reasonable cost.
Immunogenicity Assessment and Clinical Relevance Immunogenicity Assessment and Clinical Relevance
November 16, 2011 |
Escherichia coli has proven its worth as a protein expression platform. Currently, E.coli is not viewed so much as an ‘alternative’ platform, but as a viable choice for achieving high-level expression of human genes and proteins at a reasonable cost.




Publications, Reports, & Whitepapers
Vaccines: The End of Illness
This report analyzes recent trends in medicinal chemistry and evaluates their significance for advancing R&D productivity. We consider technological modalities and market dynamics, with an emphasis on outsourcing and user views on the implications of current practices.
Digital Pathology Insights: Imaging Technologies, Expert Perspectives, Standardization, and Current Outlooks
This report analyzes recent trends in medicinal chemistry and evaluates their significance for advancing R&D productivity. We consider technological modalities and market dynamics, with an emphasis on outsourcing and user views on the implications of current practices.
Ocular Disorders: Rising Therapeutics, Technologies, and Devices
New to Insight Pharma Reports is: Ocular Disorders: Rising Therapeutics, Technologies, and Devices. This report covers several companies and their approach to targeting ocular diseases including wet and dry age-related macular degeneration (AMD) while also providing alternative therapeutic options for various ocular complications.
Animal Models for Therapeutic Strategies
Animal Models for Therapeutic Strategies, an Insight Pharma Report, focuses on the use of animal models in development of novel therapeutic strategies.